Peripartum cardiomyopathy management: insights from a Latin American case report

Gabriela Zavaleta-Camacho; Javier Torres-Valencia; Karen Alayo-Rojas; Carlos Diaz-Arocutipa; José Saucedo-Chinchay

doi:10.47487/apcyccv.v5i4.422

Autores/as

Gabriela Zavaleta-Camacho Department of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Alberto Hurtado Faculty of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. https://orcid.org/0000-0002-4164-0579
Javier Torres-Valencia Department of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru. https://orcid.org/0000-0002-0941-677X
Karen Alayo-Rojas Department of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; Alberto Hurtado Faculty of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. https://orcid.org/0009-0005-3391-9739
Carlos Diaz-Arocutipa Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. https://orcid.org/0000-0002-5101-2832
José Saucedo-Chinchay Department of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru. https://orcid.org/0000-0003-4938-2241

DOI:

https://doi.org/10.47487/apcyccv.v5i4.422

Palabras clave:

Cardiomyopathies, Heart Failure, Latin America

Resumen

Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition that can occur during the late pregnancy or puerperium. A 31-year-old woman with a recent twin pregnancy presented with heart failure symptoms nine days postpartum. On admission, she had volume overload and hemodynamic compromise, which was rapidly reversed with inotropic levosimendan support. Echocardiography revealed a left ventricular ejection fraction (LVEF) of 20% with global hypokinesia. Once stabilized, she was discharged on heart failure medication, bromocriptine, and warfarin. Cardiac magnetic resonance imaging at five weeks demonstrated a preserved LVEF of 57% and no evidence of myocardial scarring or edema. During the 4-year follow-up, the patient remained stable with no new pregnancies. This case highlights the importance of considering PPCM in the differential diagnosis of heart failure in the peripartum period after excluding other etiologies. It also describes the successful use of bromocriptine in facilitating recovery of systolic function without long-term complications.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(7):827-43. doi: 10.1002/ejhf.1493.

Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(2):207-21. doi: 10.1016/j.jacc.2019.11.014.

Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, et al. Natural Course of Peripartum Cardiomyopathy. Circulation 1971;44(6):1053-61. doi: 10.1161/01.CIR.44.6.1053

Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364:k5287. doi: https://doi.org/10.1136/bmj.k5287.

Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33-8. doi: 10.1016/j.ijcard.2011.11.069.

Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: from genetics to management. Eur Heart J. 2021;42(32):3094-3102. doi: 10.1093/eurheartj/ehab458.

Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, et al. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J. 2017;38(5):349-361. doi: 10.1093/eurheartj/ehw086.

Labbene I, Arrigo M, Tavares M, Hajjej Z, Brandão JL, Tolppanen H, et al. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2017;36(1):39-42. doi: 10.1016/j.accpm.2016.02.009.

Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof- of-concept pilot study. Circulation. 2010;121(13):1465-73. doi: 10.1161/CIRCULATIONAHA.109.901496.

Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38:2671-9. doi: 10.1093/eurheartj/ehx355.

McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905-14. doi: 10.1016/j.jacc.2015.06.1309.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiol Pol. 2019;77(3):245-326. doi: 10.5603/KP.2019.0049.

Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020;41(39):3787-97. doi: 10.1093/eurheartj/ehaa940.

Jackson AM, Goland S, Farhan HA, Yaseen IF, Prameswari HS, Böhm M, et al. A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry. Eur Heart J. 2024;45(16):1430-9. doi: 10.1093/eurheartj/ehad888.

Liang Y-D, Xu Y-W, Li W-H, Wan K, Sun J-Y, Lin J-Y, et al. Left ventricular function recovery in peripartum cardiomyopathy: a cardiovascular magnetic resonance study by myocardial T1 and T2 mapping. J Cardiovasc Magn Reson. 2020;22(1):2. doi: 10.1186/s12968-019-0590-z.

Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096-105.doi: 10.1002/ejhf.586.

van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, van der Werf R, Jongbloed JD, Paulus WJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121(20):2169-75. doi: 10.1161/CIRCULATIONAHA.109.929646.

Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016;374(3):233-41. doi: 10.1056/NEJMoa1505517.

Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res. 2018;114(10):1287-1303. doi: 10.1093/cvr/cvy122.

Sliwa K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, Jackson A, Johnson MR, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2018;20(6):951-962. doi: 10.1002/ejhf.1178.